-
Wed02Oct2019Thu03Oct2019
-
Thu17Oct2019Sat19Oct2019
-
Sat02Nov2019Mon04Nov2019
-
Thu07Nov2019Sun10Nov2019
-
Fri15May2020Sat16May2020
Latest News
EVLA at different power settings found to have no significant impact...
There is no significant difference in pain and recanalisation for patients undergoing endovenous laser ablation (EVLA) at different power settings, according to the results...
Features
Private equity firm invests in UK centre performing EVLA for varicose...
A private equity firm, Palatine (Manchester, UK), has announced that it has made a “significant investment” into a UK centre—Veincentre—that provides endovenous laser ablation...
Pharmacotherapy for lymphoedema may be on the horizon
While developing specific treatment for primary lymphoedema presents an “enormous” scientific challenge, secondary lymphoedema may prove an easier target, Oliver Lyons writes for Venous...
Videos
Michael Dake (Tucson, Arizona) presented the two-year data from the VERNACULAR trial at CIRSE 2019 on 8 September in Barcelona, Spain.
Dake said: “The 24-month results from the VERNACULAR trial using the BD Venovo stent show absolutely sustained benefit in...
(Visited 186,632 times, 400 visits today)